|
|||||
|
|
Prediagnostic serum glyceraldehyde-derived advanced glycation end products and mortality among colorectal cancer patients |
|
| Authors: | Ziling Mao Jacqueline Roshelli Baker Masayoshi Takeuchi Hideyuki Hyogo Anne Tjønneland Anne Kirstine Eriksen Gianluca Severi Joseph Rothwell Nasser Laouali Verena Katzke Rudolf Kaaks Matthias B Schulze Domenico Palli Sabina Sieri Maria Santucci de Magistris Rosario Tumino Carlotta Sacerdote Jeroen W G Derksen Inger T Gram Guri Skeie Torkjel M Sandanger Jose Ramón Quirós Marta Crous-Bou Maria-Jose Sánchez Pilar Amiano Sandra M Colorado-Yohar Marcela Guevara Sophia Harlid Ingegerd Johansson Aurora Perez-Cornago Heinz Freisling Marc Gunter Elisabete Weiderpass Alicia K Heath Elom Aglago Mazda Jenab Veronika Fedirko |
| Affiliation: | 1. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA
Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA;2. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA;3. Department of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, Ishikawa, Japan;4. Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan Lifecare Clinic Hiroshima, Hiroshima, Japan;5. Danish Cancer Society Research Center, Diet, Cancer and Health, Copenhagen, Denmark Department of Public Health, University of Copenhagen, Copenhagen, Denmark;6. Danish Cancer Society Research Center, Diet, Cancer and Health, Copenhagen, Denmark;7. UVSQ, Inserm, Centre for Epidemiology and Population Health (U1018), Exposome and Heredity Team, Université Paris-Saclay, Villejuif, France;8. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany;9. Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany;10. Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network – ISPRO, Florence, Italy;11. Epidemiology and Prevention Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori di Milano Via Venezian, Milan, Italy;12. Azienda Ospedaliera Universitaria Federico II, Naples, Italy;13. Hyblean Association for Epidemiological Research, AIRE ONLUS, Ragusa, Italy;14. Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital, Turin, Italy;15. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands;16. Department of Community Medicine, UiT-The Arctic University of Norway, Tromsø, Norway;17. Public Health Directorate, Asturias, Spain;18. Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA;19. Escuela Andaluza de Salud Pública (EASP), Granada, Spain Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain;20. Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain Ministry of Health of the Basque Government, Sub Directorate for Public Health and Addictions of Gipuzkoa, San Sebastian, Spain Epidemiology of Chronic and Communicable Diseases Group, Biodonostia Health Research Institute, San Sebastián, Spain;21. Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain Research Group on Demography and Health, National Faculty of Public Health, University of Antioquia, Medellín, Colombia;22. Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain Navarra Public Health Institute, Pamplona, Spain Navarra Institute for Health Research (IdiSNA), Pamplona, Spain;23. Department of Radiation Sciences, Umeå University, Umeå, Sweden;24. Department of Odontology, Umeå university, Umeå, Sweden;25. Cancer Epidemiology Unit (CEU), Nuffield Department of Population Health, Medical Sciences Division, University of Oxford, Oxford, UK;26. Section of Nutrition and Metabolism, Nutritional Epidemiology Group, International Agency for Research on Cancer, World Health Organization (IARC-WHO), Lyon, France;27. Office of the Director, International Agency for Research on Cancer (IARC-WHO), Lyon, France;28. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK |
| Abstract: | Glyceraldehyde-derived advanced glycation end products (glycer-AGEs) could contribute to colorectal cancer development and progression due to their pro-oxidative and pro-inflammatory properties. However, the association of glycer-AGEs with mortality after colorectal cancer diagnosis has not been previously investigated. Circulating glycer-AGEs were measured by competitive ELISA. Multivariable Cox proportional hazards models were used to calculate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for associations of circulating glycer-AGEs concentrations with CRC-specific and all-cause mortality among 1034 colorectal cancer (CRC) cases identified within the European Prospective Investigation into Cancer and Nutrition (EPIC) study between 1993 and 2013. During a mean of 48 months of follow-up, 529 participants died (409 from CRC). Glycer-AGEs were statistically significantly positively associated with CRC-specific (HRQ5 vs Q1 = 1.53, 95% CI: 1.04-2.25, Ptrend = .002) and all-cause (HRQ5 vs Q1 = 1.62, 95% CI: 1.16-2.26, Ptrend < .001) mortality among individuals with CRC. There was suggestion of a stronger association between glycer-AGEs and CRC-specific mortality among patients with distal colon cancer (per SD increment: HRproximal colon = 1.02, 95% CI: 0.74-1.42; HRdistal colon = 1.51, 95% CI: 1.20-1.91; Peffect modification = .02). The highest HR was observed among CRC cases in the highest body mass index (BMI) and glycer-AGEs category relative to lowest BMI and glycer-AGEs category for both CRC-specific (HR = 1.78, 95% CI: 1.02-3.01) and all-cause mortality (HR = 2.15, 95% CI: 1.33-3.47), although no statistically significant effect modification was observed. Our study found that prediagnostic circulating glycer-AGEs are positively associated with CRC-specific and all-cause mortality among individuals with CRC. Further investigations in other populations and stratifying by tumor location and BMI are warranted. |
| Keywords: | advanced glycation end products colorectal cancer glyceraldehyde-derived advanced glycation end products mortality prospective study |
